12. Uncontrolled, significant concurrent or recent illness including, but not limited to, the following conditions: a. Cardiovascular disorders including i. Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening ii. Concurrent uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment iii. Any history of congenital long QT syndrome or iv. Any of the following within 6 months before the first dose of study treatment: • unstable angina pectoris • clinically-significant cardiac arrhythmias• stroke (including TIA, or other ischemic event) within 90 days of the first dose of study treatment • myocardial infarction • clinically significant thromboembolic event within 42 days of randomization requiring therapeutic anticoagulation.